CEFUROXIME SODIUM

Post-LOE

cefuroxime sodium

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

May 2001

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CEFUROXIME SODIUM (cefuroxime sodium) by Fresenius Kabi is mechanism of action cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Approved for including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains) and 3 more indications. First approved in 2001.

Drug data last refreshed 21h ago

Mechanism of Action

Mechanism of Action Cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.

Indications (6)

including pneumonia caused by Streptococcus pneumoniae

Worked on CEFUROXIME SODIUM at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.